Application of targeted N4BP1 inhibitor in preparation of oral squamous cell carcinoma chemotherapeutic drug

By targeting N4BP1 inhibitors and CRISPR-Cas9 technology, combined with traditional chemotherapy drugs, the problems of low sensitivity and high drug resistance of chemotherapy drugs for oral squamous cell carcinoma are solved, significantly improving the therapeutic effect and enhancing anti-tumor ability.

CN118949036APending Publication Date: 2024-11-15NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411050306.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing chemotherapeutic drugs have low sensitivity and high drug resistance problems in the treatment of oral squamous cell carcinoma, resulting in poor treatment effects and accompanied by serious side effects, limiting their application.

Method used

Using targeted N4BP1 inhibitors, the important role of N4BP1 in regulating tumor cells' sensitivity to chemotherapy drugs is verified by constructing N4BP1 knockout cell lines and using CRISPR-Cas9 technology, combined with traditional chemotherapy drugs (such as cisplatin or doxorubicin ) Improve the sensitivity of tumor cells.

Benefits of technology

It significantly improved the toxicity and efficacy of chemotherapy drugs on oral squamous cell carcinoma, enhanced the anti-tumor effect, and improved the lethality of traditional chemotherapy drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949036A_ABST
    Figure CN118949036A_ABST
Patent Text Reader

Abstract

The invention provides application of a targeted N4BP1 inhibitor in preparation of an oral squamous cell carcinoma chemotherapeutic drug, relates to the technical field of biomedicine, and provides application of the targeted N4BP1 inhibitor in preparation of the oral squamous cell carcinoma chemotherapeutic drug, and the chemotherapeutic drug is a traditional oral squamous cell carcinoma chemotherapeutic drug. In the invention, the expression of N4BP1 is negatively related to the sensitivity of oral squamous cell carcinoma cells to chemotherapeutic drugs, and the toxicity of traditional chemotherapeutic drugs (cis-platinum or doxorubicin) to the oral squamous cell carcinoma cells is remarkably improved due to the lack of N4BP1. The invention provides a biological preparation for inhibiting N4BP1. The biological preparation can enhance the treatment effect of chemotherapeutic drugs on oral squamous cell carcinoma. Knockout or inhibition of N4BP1 is combined with traditional chemotherapeutic drugs (cis-platinum and doxorubicin), so that the sensitivity of tumor cells can be improved, and the anti-tumor effect is enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to application of a targeted N4BP1 inhibitor in the preparation of a chemotherapy drug for oral squamous cell carcinoma. Background Art

[0002] Head and neck squamous cell carcinoma (HNSCC) is one of the most common forms of cancer, with the 14th highest incidence and 13th highest mortality among all cancers. More than 90% of cancer cases in the head and neck region are oral squamous cell carcinoma (OSCC), and the highest incidence and mortality rates are found on the Asian continent. According to the Global Cancer Observatory (GCO), by 2040, the incidence of OSCC will rise by approximately 40%, accompanied by an increase in mortality.

[0003] Currently, OSCC treatment options usually include a combination of multiple treatment methods, such as maxillofacial tumor resection and lymph node dissection, plastic and reconstructive surgery, radiotherapy and systemic therapy, but the overall survival rate of patients is still poor. It has been proposed that new treatment methods such as targeted therapy and immunotherapy also have certain limitations and challenges. For example, immunotherapy may have immune-related adverse reactions and drug resistance problems.

[0004] Clinical medication suggests that oral squamous cell carcinoma exhibits low sensitivity and high resistance to chemotherapeutic drugs, and high doses of chemotherapeutic drugs bring serious side effects to the body, thus limiting the application of chemotherapeutic drugs in the treatment of OSCC. Summary of the invention

[0005] The purpose of the present invention is to solve the technical problem that the application of chemotherapy drugs in the treatment of OSCC is limited in the prior art.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] Application of a targeted N4BP1 inhibitor in the preparation of a chemotherapy drug for oral squamous cell carcinoma, wherein the chemotherapy drug is a traditional chemotherapy drug for oral squamous cell carcinoma.

[0008] Preferably, the targeted N4BP1 inhibitor is used to enhance the toxicity of conventional chemotherapy drugs to oral squamous cell carcinoma.

[0009] Preferably, the traditional chemotherapy drug is cisplatin or doxorubicin.

[0010] The present application also provides a verification experiment that N4BP1 plays an important role in regulating the sensitivity of tumor cells to chemotherapeutic drugs, comprising the following steps:

[0011] S1: Select human oral squamous cell carcinoma cell line and construct N4BP1 knockout cell line;

[0012] S2: Detect the effect of N4BP1 knockout on the sensitivity of tumor cells to chemotherapeutic drugs.

[0013] Preferably, in said S1, two human oral squamous cell carcinoma cell lines SCC9 and CAL27 are selected; and the N4BP1 knockout cell line is constructed by CRISPR-Cas9 technology.

[0014] Preferably, the SCC9 and CAL27 knockout cell lines are treated with different concentrations of chemotherapeutic drugs for 24 hours; and the CCK8 method is used to detect the inhibitory effect of the chemotherapeutic drugs on cell proliferation.

[0015] Preferably, the chemotherapy drug is doxorubicin, and a fluorescence microscope is used to track the entry of doxorubicin into cells.

[0016] The present invention found that the expression of N4BP1 was negatively correlated with the sensitivity of oral squamous cell carcinoma cells to chemotherapeutic drugs, and the loss of N4BP1 significantly increased the toxicity of traditional chemotherapeutic drugs (cisplatin or doxorubicin) to oral squamous cell carcinoma cells. The present invention provides a biological preparation for inhibiting N4BP1, which can enhance the therapeutic efficacy of chemotherapeutic drugs for oral squamous cell carcinoma. Knocking out or inhibiting N4BP1 combined with traditional chemotherapeutic drugs (cisplatin, doxorubicin) can increase the sensitivity of tumor cells and enhance the anti-tumor effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 These are relevant verification figures for the down-regulation of N4BP1 expression in cisplatin-treated tumor cells in Example 1 of the present invention, wherein (A) RT-PCR detected the relative expression level of N4BP1 mRNA in SCC9 and CAL27 cells under 50 μM cisplatin stimulation conditions; (B) Western Blot detected the relative expression level of N4BP1 protein in SCC9 and CAL27 cells under 50 μM cisplatin stimulation conditions; wherein * indicates P<0.05; ** indicates P<0.01; *** indicates P<0.001.

[0018] Figure 2 This is a schematic diagram of RT-PCR detection of up-regulated expression of N4BP1 in tumor cells treated with doxorubicin in Example 2 of the present invention, where * indicates P<0.05; ** indicates P<0.01. ;

[0019] Figure 3 This is a schematic diagram of WB detection in Example 2 of the present invention.

[0020] Figure 4 The Western Blot in Example 3 of the present invention verifies the knockout effect of N4BP1 in SCC9 and CAL27 cell lines, wherein (A) and (B) respectively represent the relative expression levels of N4BP1 protein after knockout of N4BP1 in SCC9 and CAL27 cells detected by Western Blot.

[0021] Figure 5 This is a verification experiment diagram of the effect of gradient concentration of cisplatin on tumor cell proliferation detected by CCK8 in Example 3 of the present invention, wherein * indicates P<0.05; ** indicates P<0.01; *** indicates P<0.001.

[0022] Figure 6 The CCK8 method in Example 3 of the present invention detects the effect of cisplatin on tumor cell proliferation, where * indicates P<0.05; ** indicates P<0.01; *** indicates P<0.001.

[0023] Figure 7 This is a verification experiment diagram of the CCK8 method in Example 3 of the present invention for detecting the effect of doxorubicin on tumor cell proliferation, wherein * indicates P<0.05; ** indicates P<0.01; *** indicates P<0.001.

[0024] Figure 8 This is a diagram of the validation experiment for immunofluorescence detection of doxorubicin entering the nucleus of tumor cells. DETAILED DESCRIPTION

[0025] The present invention is further described in detail below in conjunction with specific embodiments.

[0026] Application of a targeted N4BP1 inhibitor in the preparation of a chemotherapy drug for oral squamous cell carcinoma, wherein the chemotherapy drug is a traditional chemotherapy drug for oral squamous cell carcinoma.

[0027] In one embodiment, the targeted N4BP1 inhibitor is used to enhance the toxicity of conventional chemotherapy drugs to oral squamous cell carcinoma.

[0028] In one embodiment, the traditional chemotherapy drug is cisplatin or doxorubicin.

[0029] The present application also provides a verification experiment for verifying that N4BP1 plays an important role in regulating the sensitivity of tumor cells to chemotherapeutic drugs, which comprises the following steps:

[0030] S1: Select human oral squamous cell carcinoma cell line and construct N4BP1 knockout cell line;

[0031] In one embodiment, two human oral squamous cell carcinoma cell lines SCC9 and CAL27 are selected; and a N4BP1 knockout cell line is constructed using CRISPR-Cas9 technology;

[0032] S2: Detect the effect of knocking out N4BP1 on the sensitivity of tumor cells to chemotherapeutic drugs:

[0033] The SCC9 and CAL27 knockout cell lines were treated with different concentrations of chemotherapy drugs for 24 hours, and the CCK8 method was used to detect the inhibitory effect of the chemotherapy drugs on cell proliferation. The chemotherapy drugs were cisplatin or doxorubicin.

[0034] In one embodiment, when the chemotherapeutic drug is doxorubicin, a fluorescence microscope is used to track the entry of doxorubicin into cells.

[0035] The following is an explanation of the above content in combination with specific verification experiments:

[0036] Example 1: Changes in N4BP1 expression in two oral squamous cell carcinoma cells (CCL2 and CAL27) treated with cisplatin or doxorubicin:

[0037] A1: Two oral squamous cell carcinoma cells (CCL2 and CAL27) treated with cisplatin. The results are as follows Figure 1 As shown in the figure, with the extension of the action time, the mRNA and protein levels of N4BP1 decreased significantly, suggesting that N4BP1 may play an important role in regulating the sensitivity of tumor cells to chemotherapeutic drugs.

[0038] A2: Two oral squamous cell carcinoma cells (CCL2 and CAL27) were treated with doxorubicin. The results are as follows Figure 2 As shown, the expression of N4BP1 was upregulated, especially after 48 h of treatment.

[0039] Please participate Figure 2 and Figure 3 , with the extension of the action time, the mRNA and protein levels of N4BP1 were significantly upregulated, suggesting that N4BP1 may play an important role in regulating the sensitivity of tumor cells to chemotherapeutic drugs.

[0040] Example 2: Verification of the role of N4BP1 in tumor killing by chemotherapy drugs:

[0041] B1: Two human oral squamous cell carcinoma cell lines, SCC9 and CAL27, were selected to construct N4BP1 knockout cell lines using CRISPR-Cas9 technology. The construction results are shown in the figure. Figure 4 shown.

[0042] B2: Detect the effect of knocking out N4BP1 on the sensitivity of tumor cells to cisplatin:

[0043] SCC9 and CAL27 knockout cell lines were treated with different concentrations of cisplatin for 24 hours, and the inhibitory effect of cisplatin on cell proliferation was detected by CCK8 assay. Figure 5 ,The results showed that when the concentration reached above 100 μM, the sensitivity of SCC9 and CAL27 cells lacking N4BP1 to cisplatin was significantly enhanced compared with the control group.

[0044] The above results were verified by treating tumor cells with 100 μM cisplatin at different time points. The proliferation of cells in the control group (Sg-Vector) and the N4BP1 knockout group (Sg-N4BP1) under the stimulation of 100 μM cisplatin was detected by CCK method. Figure 6 ,and Figure 5 The results were consistent, and the loss of N4BP1 effectively enhanced the tumor killing effect of cisplatin.

[0045] B3: Detect the killing effect of doxorubicin on N4BP1-deficient cell lines.

[0046] The proliferation of cells in the control group (Sg-Vector) and the N4BP1 knockout group (Sg-N4BP1) under doxorubicin stimulation was detected by CCK-8 method. Figure 7 As shown, cells with N4BP1 knockout showed better sensitivity to doxorubicin.

[0047] Since doxorubicin spontaneously emits red fluorescence, the entry of doxorubicin into the cell nucleus is the key to its tumor-killing effect. In order to verify whether N4BP1 affects the entry of doxorubicin into the cell nucleus, the control group (Sg-Vector) cells and the N4BP1 knockout group (Sg-N4BP1) cells were treated with doxorubicin at the same time, and then the entry of doxorubicin into the cells was tracked using a fluorescence microscope.

[0048] The results are as follows Figure 8 As shown, when control cells and N4BP1-deficient cells were treated with the same concentration and time, the amount of doxorubicin entering the cells was significantly increased after knocking out N4BP1 deficiency.

[0049] The following are some of the experimental steps required for use in the above examples:

[0050] (1) Cell culture

[0051] The two oral squamous cell carcinoma cell lines (CCL9 and CAL27) required for the experiment were cultured in DMEM containing 10% fetal bovine serum, 1% streptomycin and penicillin in a constant temperature incubator at 5% CO2 and 37°C.

[0052] (2) Construction of CRISPR-Cas9 knockout plasmid

[0053] ①EpiCRISPR-Cas9 plasmid vector digestion

[0054] Table 1 Enzyme digestion system

[0055]

[0056] The mixture was placed in a 50°C water bath for 4 hours to improve the enzyme digestion effect.

[0057] ② Recycling of enzyme digestion products

[0058] The digested product was mixed with DNA loading buffer at a ratio of 10:1 and added to 1% agarose gel for electrophoresis. Further purification was performed according to the instructions of the recovery gel DNA purification kit.

[0059] ③ Primer annealing

[0060] Table 2 Construction of sgRNA primers for knockout N4BP1 cell lines

[0061]

[0062] Table 3 Plasmid construction annealing system

[0063]

[0064] The mixture was placed at 94°C for 20 minutes and then cooled to room temperature.

[0065] ④ Vector connection: Place the following mixture in a 16°C water bath and connect overnight.

[0066] Table 4 Plasmid construction and connection system

[0067]

[0068] ⑤ Plasmid transformation plate

[0069] Take 5 μL of the ligation product and 10 μL of DH5α competent cells, mix gently, incubate on ice for 20 minutes, heat shock at 42°C for 30 seconds, immediately put back on ice, and let stand for 2 minutes. Add 200 μL of LB medium without ampicillin resistance to the EP tube, place the EP tube at 37°C, and pre-shake (or resuscitate) for 45 minutes. Transfer the pre-shaken bacterial solution to the LB plate containing ampicillin resistance, and use a sterile coating rod to evenly spread the cell mixture on the surface of the culture medium. Invert the plate, place it in a 37°C incubator, and culture overnight (usually about 12-16 hours), and finally pick the bacteria and amplify.

[0070] ⑥Extract plasmid and sequence: Extract the plasmid according to the manufacturer's instructions and verify its sequence by sequencing to confirm whether the plasmid is successfully constructed.

[0071] (3) Construction of stable cell lines

[0072] ① Cell preparation: The day before transfection, evenly spread the digested cells in a 6-well cell culture plate to ensure that the cell density is about 70% during transfection. Determine the number of wells to be used according to experimental requirements, and set up a blank well, which does not contain transfection reagent.

[0073] ② Preparation of transfection reagent: Before transfection, replace the culture medium with serum-free culture medium. The transfection process is divided into two tubes, A and B. In tube A, dilute 1.5 μg of plasmid with 100 μL Opti-MEM and then let it stand for 5 minutes. In tube B, dilute 3 μL of Lipofectamine 2000 transfection reagent with 100 μL Opti-MEM and also let it stand for 5 minutes. Mix the solutions in tubes A and B and let them stand at room temperature for 20 minutes.

[0074] ③ Transfection operation: Gently add the above mixed solution to each well, shake to mix, and place the 6-well plate in an incubator at 37°C and 5% CO2 for incubation. After 6-8 hours, replace with fresh complete medium and return to the incubator for continued incubation.

[0075] ④Drug screening and identification: 48 hours after transfection, use puromycin to screen the knockout cell line. Use Western Blot analysis to verify whether the target protein is successfully knocked out.

[0076] (4) CCK-8 method to detect the sensitivity of tumor cells to chemotherapy drugs

[0077] The digested cells were seeded in a 96-well plate at a density of 3,000 cells and cultured for 8 hours until the cells adhered to the wall. The complete culture medium containing the required concentration of chemotherapy drugs was replaced. According to the experimental design, the CCK8 kit was used to detect cell viability at different time points.

[0078] (5) Protein immunoblotting

[0079] Protein extraction: After washing the digested cells with PBS, add an appropriate amount of RIPA lysis buffer to ensure that the cells are fully lysed. Place on ice and shake for 45 minutes, centrifuge at 12000r / min, 4℃ for 15 minutes, and take the supernatant. Add 5× protein loading buffer and boil in a 105℃ metal bath for 5 minutes, or heat at 95℃ for 10 minutes.

[0080] Gel electrophoresis and protein immunodetection:

[0081] ① Electrophoresis: Put the prepared gel into the electrophoresis tank, add the electrophoresis solution and gently remove the comb, mix the protein sample with a pipette and add it to each well in turn. Turn on the electrophoresis tank power supply, set the starting voltage to 80V, and when the protein marker begins to separate clear bands in the separation gel, increase the voltage to 120V. If the protein marker is completely separated, or the bromophenol blue migrates to a specific position at the bottom of the gel (such as 1cm), the electrophoresis can be ended.

[0082] ② Transfer: Place the transfer clip in the water tray filled with transfer fluid. This clip usually has two sides, black and white, open with the black side facing down and the white side facing up. Place a sponge pad on the blackboard and filter paper on it, open the glass plate, let the gel fall onto the filter paper, and adjust the position of the gel to ensure that it does not dry. Take a 0.45μm PVDF membrane and put it in methanol to activate for 15 seconds (if the molecular weight is particularly small, a 0.22μm PVDF membrane can be used), then remove it and put it in water to deactivate, after wetting with transfer fluid, carefully place it on the gel, and gently rinse with transfer fluid to remove bubbles. Put the membrane, filter paper, and sponge pad in order, gently close the transfer clip, ensure that the sponge pad and filter paper are wetted with transfer fluid, and put the clip in the transfer tank according to the principle of black to black and red to white. Inject transfer fluid into the transfer tank, turn on the power, adjust the current to 300mA, and set the appropriate transfer time according to the molecular weight of the target protein. For a molecule of 1 kDa, this takes approximately 1 minute.

[0083] ③ Blocking: After the transfer is completed, the PVDF membrane needs to be taken out and placed in 5% skim milk and blocked on a shaker at room temperature for 2 hours to ensure that the milk is fully bound to all binding sites on the membrane, thereby minimizing the possibility of nonspecific binding.

[0084] ④ Antibody incubation: Select the corresponding primary antibody according to the experimental requirements, dilute the antibody according to the manufacturer's recommended concentration, then add a sufficient amount of diluted antibody to the PVDF membrane, and then incubate the membrane in a 4°C refrigerator overnight. After incubation, wash the membrane three times with 1×TBST washing solution for 5 minutes each time to remove residual primary antibody. Select the corresponding secondary antibody and dilute it with 5% skim milk at a ratio of 1:2000, and incubate at room temperature for 2 hours. After incubation, wash the membrane three times with 1×TBST washing solution for 20 minutes each time to remove residual secondary antibody.

[0085] ⑤ Development: ECL luminescent solution is composed of liquid A and liquid B, which need to be mixed in a 1:1 ratio. The key to this step is to ensure that the two liquids are mixed evenly and that they are used immediately after being prepared to avoid long-term storage causing the solution to become ineffective. Evenly drop the prepared ECL luminescent solution on the membrane and use a chemiluminometer to develop the membrane. The development time and number of sheets can be adjusted according to different protein antibodies.

[0086] (6) Real-time quantitative PCR (RT-PCR)

[0087] Extraction of total RNA from cells:

[0088] Digest the cells with trypsin to separate them from the dish, pipette the cells into an RNase-Free EP tube, centrifuge at 1000r / min for 5 minutes, discard the supernatant to collect the cell pellet. Add 1mL of Trizol reagent to the centrifuge tube and mix by blowing repeatedly. If RNA extraction cannot be performed in time, the cell pellet can be directly placed in a -80℃ freezer. Place the sample at room temperature for 5 minutes. To completely separate the nucleic acid-protein complex, add 200μL of chloroform, then shake vigorously for 15 seconds, and then let it stand at room temperature for 3 minutes. Then centrifuge at 12000r / min for 15 minutes at 4℃, so that the sample will be separated into three layers. Transfer the supernatant to a new RNase-Free EP tube, add an equal amount of isopropanol to precipitate RNA, and place it at room temperature for 10 minutes or in a -20℃ freezer for 1 hour. Centrifuge at 12000r / min for 10 minutes at 4°C. After centrifugation, we will see a gelatinous precipitate on the side and bottom of the test tube. At this time, you need to carefully remove the supernatant. Next, wash the RNA precipitate with 1mL of 75% ethanol, centrifuge again at 7500r / min for 5 minutes at 4°C, remove the supernatant, and repeat this step twice. Place the dried RNA precipitate at room temperature for about 10-30 minutes, add 20-100μL of RNase-Free enzyme ultrapure water, pipette several times, place in a 55-60°C water bath for 10 minutes to dissolve the RNA, and store at -80°C.

[0089] Reverse transcription of RNA to cDNA:

[0090] ① Take 8 tubes of RNase-Free and place them on ice. II Reverse Transcriptase Instructions Reverse transcription of RNA to synthesize cDNA.

[0091] Table 5 Reverse transcription reaction system

[0092]

[0093] ② Transfer the mixture to a PCR instrument and perform a reverse transcription reaction. The specific temperature settings are: 37°C for 15 minutes and 85°C for 5 seconds. After the reaction is completed, the product can be directly used for subsequent PCR reactions, or stored in a -20°C refrigerator for later use.

[0094] RT-PCR:

[0095] ① Dilute the cDNA product obtained by the above reversal 5 times, take 0.2μL of upstream primer, 0.2μL of downstream primer, 5μL of 5×SYBR Green, 2.6μL of RNase-Free ddH2O and 2μL of diluted cDNA product and add them to the 96-well plate. Put the 96-well plate with the sample into a low-speed centrifuge, centrifuge at 3500r / min for 3 minutes, and put the 96-well plate into the PCR instrument after centrifugation.

[0096] Table 6 PCR reaction conditions

[0097]

[0098]

[0099] ②Use 2 -△△C Data analysis was performed using the T method.

[0100] Table 7 RT-PCR primers

[0101]

[0102] In summary, the present application provides an application of a targeted N4BP1 inhibitor in the preparation of oral squamous cell carcinoma chemotherapy drugs. By knocking out or inhibiting N4BP1 in combination with traditional chemotherapy drugs (cisplatin or doxorubicin), the sensitivity of tumor cells can be increased and the anti-tumor effect can be improved.

Claims

1. Use of a targeted N4BP1 inhibitor in the preparation of a chemotherapy drug for oral squamous cell carcinoma, characterized in that: The chemotherapy drug is a traditional chemotherapy drug for oral squamous cell carcinoma.

2. Use of the targeted N4BP1 inhibitor according to claim 1 in the preparation of a chemotherapy drug for oral squamous cell carcinoma, characterized in that: The targeted N4BP1 inhibitor is used to increase the toxicity of traditional chemotherapy drugs to oral squamous cell carcinoma.

3. Use of the targeted N4BP1 inhibitor according to claim 1 in the preparation of a chemotherapy drug for oral squamous cell carcinoma, characterized in that: The traditional chemotherapy drug is cisplatin or doxorubicin.

4. A validation experiment that N4BP1 plays an important role in regulating the sensitivity of tumor cells to chemotherapeutic drugs, characterized in that: The following steps are involved: S1: Select human oral squamous cell carcinoma cell line and construct N4BP1 knockout cell line; S2: Detect the effect of N4BP1 knockout on the sensitivity of tumor cells to chemotherapeutic drugs.

5. The verification experiment of claim 4 that N4BP1 plays an important role in regulating the sensitivity of tumor cells to chemotherapeutic drugs, characterized in that: In the S1, two human oral squamous cell carcinoma cell lines SCC9 and CAL27 were selected; and the N4BP1 knockout cell line was constructed by CRISPR-Cas9 technology.

6. The verification experiment of claim 5 that N4BP1 plays an important role in regulating the sensitivity of tumor cells to chemotherapeutic drugs, characterized in that: SCC9 and CAL27 knockout cell lines were treated with different concentrations of chemotherapeutic drugs for 24 h, and the CCK8 method was used to detect the inhibitory effect of chemotherapeutic drugs on cell proliferation.

7. The verification experiment of claim 6 that N4BP1 plays an important role in regulating the sensitivity of tumor cells to chemotherapeutic drugs, characterized in that: The chemotherapy drug is doxorubicin, and a fluorescence microscope is used to track the entry of doxorubicin into cells.